Gunnar Soderdahl
Overview
Explore the profile of Gunnar Soderdahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al.
EBioMedicine
. 2024 Oct;
109:105385.
PMID: 39395230
Background: Immunocompromised patients with primary and secondary immunodeficiencies have shown impaired responses to SARS-CoV-2 mRNA vaccines, necessitating recommendations for additional booster doses. However, longitudinal data reflecting the real-world impact of...
2.
Muller T, Gao Y, Wu J, Ribeiro O, Chen P, Bergman P, et al.
Cell Host Microbe
. 2024 Jan;
32(2):156-161.e3.
PMID: 38211584
T cells are critical in mediating the early control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection. However, it remains unknown whether memory T cells can effectively cross-recognize...
3.
Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al.
EBioMedicine
. 2023 Jul;
94:104700.
PMID: 37453361
Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective clinical trial cohorts with respect to long-term immunogenicity-related responses in these patient...
4.
Muller T, Sekine T, Trubach D, Niessl J, Chen P, Bergman P, et al.
Sci Transl Med
. 2023 Jul;
15(704):eadg9452.
PMID: 37437015
Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in individuals with various immunodeficiencies. Given the increased antibody evasion properties of emerging SARS-CoV-2 subvariants, it is necessary to assess...
5.
Gao Y, Cai C, Wullimann D, Niessl J, Rivera-Ballesteros O, Chen P, et al.
Immunity
. 2022 Aug;
55(9):1732-1746.e5.
PMID: 35961317
Many immunocompromised patients mount suboptimal humoral immunity after SARS-CoV-2 mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T cells post-mRNA vaccination in healthy individuals and patients with various...
6.
Cuapio A, Boulouis C, Filipovic I, Wullimann D, Kammann T, Parrot T, et al.
Mol Med
. 2022 Feb;
28(1):20.
PMID: 35135470
Adaptive immune responses have been studied extensively in the course of mRNA vaccination against COVID-19. Considerably fewer studies have assessed the effects on innate immune cells. Here, we characterized NK...
7.
Healy K, Pin E, Chen P, Soderdahl G, Nowak P, Mielke S, et al.
Med
. 2022 Jan;
3(2):137-153.e3.
PMID: 35075450
Background: Immunocompromised individuals are highly susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Whether vaccine-induced immunity in these individuals involves oral cavity, a primary site of infection, is...
8.
Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, et al.
EBioMedicine
. 2021 Dec;
74:103705.
PMID: 34861491
Background: Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate safety and efficacy...
9.
Schnitzbauer A, Filmann N, Adam R, Bachellier P, Bechstein W, Becker T, et al.
Ann Surg
. 2020 Sep;
272(5):855-862.
PMID: 32889867
Objective: The aim of this study was to evaluate the survival benefit of sirolimus in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) (exploratory analysis of the SiLVER-trial). Summary...
10.
Lindner P, Hagman H, Soderdahl G
Lakartidningen
. 2020 Apr;
117.
PMID: 32314327
Surgical treatment of liver metastases from colorectal cancer (CLM) is the only treatment option with curative potential; however, only about 15% to 20% of the patients seen at major hospitals...